oral once-daily sGC activator

Ph. II for CKD + diabetic neuropathy

from cell-based HTS + opt

J. Med. Chem., Apr. 19, 2021

Bayer AG, Wuppertal, DE

BAY-1101042-(runcaciguat)

The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II for chronic kidney disease and diabetic retinopathy. sGC is…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: